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Background
In the current international guidelines, intra-aortic 
balloon pump (IABP) counterpulsation is considered a 
class I treatment for acute myocardial infarction 
complicated by cardiogenic shock. However, evidence is 
based mainly on registry data, and there is a paucity of 
randomized clinical trials.
Methods
Objective: To test the hypothesis that IABP counter-
pulsation, as compared with the best available medical 
therapy alone, results in a reduction in mortality among 
patients with acute myocardial infarction complicated by 
cardiogenic shock for whom early revascularization is 
planned.
Design: Randomized, prospective, open-label, multicenter 
trial.
Setting: Th irty-seven centers in Germany.
Subjects: All adults had acute myocardial infarction 
complicated by cardiogenic shock and were expected to 
undergo early revascularization (by means of percu-
taneous coronary intervention or bypass surgery).
Intervention: After enrollment, 600 patients were randomly 
assigned to intra-aortic balloon counterpulsation (IABP 
group, 301 patients) or no IABP counterpulsation 
(control group, 299 patients).
Outcomes: Th e primary eﬃ  cacy endpoint is 30-day all-
cause mortality.
Results
At 30 days, 119 patients in the IABP group (39.7%) and 
123 patients in the control group (41.3%) had died 
(relative risk with IABP, 0.96; 95% conﬁ dence interval, 
0.79 to 1.17; P = 0.69). Th ere were no signiﬁ cant diﬀ er-
ences in secondary endpoints or in process-of-care 
measures, including the time to hemodynamic stabiliza-
tion, the length of stay in the intensive care unit, serum 
lactate levels, the dose and duration of catecholamine 
therapy, and renal function.
Conclusions
Th e use of IABP counterpulsation did not signiﬁ cantly 
reduce 30-day mortality in patients with acute myocardial 
infarction complicated by cardiogenic shock for whom an 




Cardiogenic shock complicates 7% to 10% of patients 
with acute myocardial infarction and carries a mortality 
rate approaching 70% to 80% [1]. Intra-aortic balloon 
pump (IABP) counterpulsation has been used routinely 
as an adjuvant treatment for myocardial infarction 
compli cated by cardiogenic shock on the basis of evi-
dence that it is associated with hemodynamic improve-
ments [2]. Given the lack of randomized clinical trials, 
recommendations for adjunctive therapy in this high-risk 
population have been based only on pathophysiological 
assumptions and expert opinion.© 2010 BioMed Central Ltd
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An IABP is a device placed in the descending thoracic 
aorta that inﬂ ates with diastole, increasing upstream 
coronary perfusion, and that deﬂ ates with systole, 
decreas ing left ventricular (LV) afterload and, in turn, 
overall myocardial oxygen demand for a given cardiac 
output in the setting of cardiogenic shock. Th e use of 
IABPs as a bridge to support LV function originated in 
the 1960s, when coronary artery bypass surgery was just 
becoming available. Today, IABP counterpulsation is 
considered one of the most widely used mechanical assist 
devices in hemodynamically unstable cardiac patients.
Th e international guidelines endorsed the use of IABP 
in treating cardiogenic shock post-myocardial infarction 
with class 1 recommendation [3,4], despite the lack of ade-
quately powered randomized trials and the recent meta-
analysis data that show limited eﬃ  cacy of IABP use [5].
Th e Intra-aortic Balloon Pump in Cardiogenic Shock II 
(IABP-SHOCK II) trial was a prospective multicenter 
randomized trial conducted at 37 German medical 
centers over a 3-year period. Six hundred patients with 
acute myocardial infarction complicated by cardiogenic 
shock were randomly assigned in a 1:1 ratio to either 
IABP or no IABP. Th ere were no signiﬁ cant diﬀ erences 
between the groups in terms of baseline characteristics 
or clinical course before random assignment. Th e major 
outcome was 30-day all-cause mortality. At 30 days, there 
was no signiﬁ cant diﬀ erence in relative risk for death 
between the two groups (relative risk of death with IABP, 
0.96; 95% conﬁ dence interval, 0.79 to 1.17; P  =  0.69). 
Th ere were no signiﬁ cant diﬀ erences in secondary end-
points and process-of-care outcomes (that is, lactate, 
C-reactive protein levels, renal function, and Simpliﬁ ed 
Acute Physiology Score II). Importantly, IABP was not 
associated with any signiﬁ cant increase in adverse events, 
including similar rates of reinfarction, stent thrombosis, 
bleeding, sepsis, or stroke. Th is multicenter randomized 
controlled study was well designed in the setting of 
cardiogenic shock with excellent recruitment of subjects 
based on eligibility.
However, general issues with this trial deserve con-
sideration. Th e control and IABP groups had similar low 
mortality rates of 40% compared with previous registries 
and randomized clinical trials, which reported mortality 
rates of over 65%. Th is suggests that the patients studied in 
this trial had less severe cardiovascular de com pen sa tion 
and may not represent the highest-risk patient cohort with 
severe cardiogenic shock. Second, there was crossover of 
10% of the control group to IABP therapy and a more 
frequent use of left ventricular assist devices (LVADs) in 
control patients (7.4% versus 3.7%), and both of these 
factors might decrease the control group mortality if IABP 
and LVAD use is beneﬁ cial. Th ird, the timing of IABP 
insertion was not controlled for. Fourth, the study reports 
only short-term results. Clearly, cardiac mortality is best 
assessed by 6- and 12-month mortality rates, if not longer. 
For example, the SHOCK trial did not show survival diﬀ er-
ences at 30 days but did see a survival beneﬁ t at 6 months 
[6]. Th ose longer-term results from this trial are needed to 
conﬁ rm the neutral eﬀ ect of IABP treatment.
Recommendation
In view of the lack of prior controlled clinical trials or 
other convincing evidence, this study challenges the 
current level I guideline recommendations for the use of 
IABP counterpulsation in patients with acute myocardial 
infarction complicated by cardiogenic shock. In this 
setting, the routinely used IABP counterpulsation need 
not be the default therapeutic approach.
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